Anebulo Pharmaceuticals Inc (ANEB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Anebulo Pharmaceuticals Inc (ANEB) has a cash flow conversion efficiency ratio of -0.165x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.31 Million) by net assets ($7.94 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Anebulo Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Anebulo Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Anebulo Pharmaceuticals Inc (ANEB) financial obligations for a breakdown of total debt and financial obligations.
Anebulo Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Anebulo Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vision Sigma
TA:VISN
|
0.039x |
|
The Union Mosaic Industry Public Company Limited
BK:UMI
|
0.025x |
|
Assura PLC
LSE:AGR
|
0.042x |
|
Niraj Cement Structurals Limited
NSE:NIRAJ
|
-0.097x |
|
Seko S.A.
WAR:SEK
|
-0.002x |
|
Woojin I&S Co Ltd
KO:010400
|
0.020x |
|
Lammhults Design Group AB (publ)
ST:LAMM-B
|
0.029x |
|
Arima Communications Corp
TW:8101
|
-0.072x |
Annual Cash Flow Conversion Efficiency for Anebulo Pharmaceuticals Inc (2020–2025)
The table below shows the annual cash flow conversion efficiency of Anebulo Pharmaceuticals Inc from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see ANEB market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $11.66 Million | $-6.35 Million | -0.545x | +74.33% |
| 2024-06-30 | $3.81 Million | $-8.09 Million | -2.122x | -132.34% |
| 2023-06-30 | $10.60 Million | $-9.68 Million | -0.913x | -153.11% |
| 2022-06-30 | $15.07 Million | $-5.44 Million | -0.361x | -58.62% |
| 2021-06-30 | $21.41 Million | $-4.87 Million | -0.227x | -323.19% |
| 2020-06-30 | $2.80 Million | $-150.77K | -0.054x | -- |
About Anebulo Pharmaceuticals Inc
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical tria… Read more